Squarepoint Ops LLC Acquires 112,250 Shares of Agios Pharmaceuticals, Inc. $AGIO

Squarepoint Ops LLC increased its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 53.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 321,138 shares of the biopharmaceutical company’s stock after acquiring an additional 112,250 shares during the period. Squarepoint Ops LLC’s holdings in Agios Pharmaceuticals were worth $11,917,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Sei Investments Co. boosted its holdings in Agios Pharmaceuticals by 342.8% during the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 49,198 shares in the last quarter. SCS Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $22,743,000. Seven Fleet Capital Management LP acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $864,000. GW&K Investment Management LLC lifted its position in shares of Agios Pharmaceuticals by 41.5% during the 4th quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock worth $32,863,000 after buying an additional 354,359 shares during the period. Finally, Erste Asset Management GmbH lifted its position in shares of Agios Pharmaceuticals by 1.4% during the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after buying an additional 40,000 shares during the period.

Analyst Upgrades and Downgrades

AGIO has been the topic of a number of analyst reports. Truist Financial lowered their price target on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. HC Wainwright lifted their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Bank of America boosted their target price on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Citigroup upped their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $41.25.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. This trade represents a 35.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.40% of the company’s stock.

Agios Pharmaceuticals Trading Up 3.2%

Shares of AGIO stock opened at $34.63 on Thursday. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00. The firm’s 50 day moving average is $35.42 and its 200-day moving average is $31.99. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -4.94 and a beta of 0.60.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The company had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. On average, equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -5.82 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.